Zimmer Biomet Holdings Inc
$ 88.17
-1.63%
10 Jun - close price
- Market Cap 17,415,492,000 USD
- Current Price $ 88.17
- High / Low $ 90.50 / 88.11
- Stock P/E 23.32
- Book Value 65.53
- EPS 3.86
- Next Earning Report 2026-08-06
- Dividend Per Share $0.96
- Dividend Yield 1.07 %
- Next Dividend Date 2026-07-31
- ROA 0.04 %
- ROE 0.06 %
- 52 Week High 107.45
- 52 Week Low 79.12
About
Zimmer Biomet is a publicly traded medical device company. The company is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.
Analyst Target Price
$98.70
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-28 | 2026-02-10 | 2025-11-05 | 2025-08-07 | 2025-05-05 | 2025-02-06 | 2024-10-30 | 2024-08-07 | 2024-05-02 | 2024-02-08 | 2023-11-07 | 2023-08-01 |
| Reported EPS | 2.09 | 2.42 | 1.16 | 0.77 | 0.91 | 2.31 | 1.74 | 2.01 | 1.94 | 2.2 | 1.65 | 1.82 |
| Estimated EPS | 1.86 | 2.4 | 0.93 | 1.18 | 0.87 | 2.29 | 1.74 | 1.99 | 1.87 | 2.16 | 1.6 | 1.81 |
| Surprise | 0.23 | 0.02 | 0.23 | -0.41 | 0.04 | 0.02 | 0 | 0.02 | 0.07 | 0.04 | 0.05 | 0.01 |
| Surprise Percentage | 12.3656% | 0.8333% | 24.7312% | -34.7458% | 4.5977% | 0.8734% | 0% | 1.005% | 3.7433% | 1.8519% | 3.125% | 0.5525% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 2.01 |
| Currency | USD |
Previous Dividend Records
| Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-04-30 | 2026-01-30 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 | 2024-01-31 |
| Amount | $0.24 | $0.24 | $0.24 | $0.24 | $0.24 | $0.24 | $0.24 | $0.24 | $0.24 | $0.24 |
Next Dividend Records
| Dividend per share (year): | $0.96 |
| Dividend Yield | 1.07% |
| Next Dividend Date | 2026-07-31 |
| Ex-Dividend Date | 2026-06-25 |
Recent News: ZBH
2026-06-11 07:09:09
Brandes Investment Partners LP significantly increased its stake in Zimmer Biomet Holdings, Inc. by 215.3% during the fourth quarter, now owning 48,863 shares valued at approximately $4.39 million. Despite mixed analyst sentiment with a consensus "Hold" rating and a price target of $102.70, Zimmer Biomet reported strong quarterly results, surpassing EPS and revenue estimates. The company also declared a $0.24 quarterly dividend, reflecting a 1.1% annualized yield.
2026-06-10 17:09:00
Zimmer Biomet Holdings Inc. (ZBH) shares fell 1.63% to $88.17 on Wednesday, underperforming the broader market as the S&P 500 and Dow Jones Industrial Average also experienced declines. The stock closed 18.58% below its 52-week high reached on August 26th.
2026-06-10 08:38:57
Goldman Sachs Group Inc. increased its stake in Zimmer Biomet Holdings, Inc. by 24.4% in the fourth quarter, now holding over 1 million shares valued at approximately $91.6 million. Zimmer Biomet reported strong quarterly results, with EPS and revenue beating analyst expectations, and declared a $0.24 quarterly dividend. The stock currently has a "Hold" rating from analysts with a consensus price target of $102.70.
2026-06-09 22:38:49
Zimmer Biomet Holdings Inc. (ZBH) saw its stock advance by 2.70% on Tuesday, closing at $89.63. This performance outpaced the broader market, as the Dow Jones Industrial Average rose slightly while the S&P 500 Index declined. The company's stock currently sits 17.23% below its 52-week high reached in August.
2026-06-09 19:38:29
Fiera Capital Corp significantly increased its stake in Stryker Corporation by 60.5% in the fourth quarter, holding 46,278 shares valued at approximately $16.3 million. This increase occurred despite Stryker reporting first-quarter earnings below expectations with an EPS of $2.60 and revenue of $6.02 billion, missing analyst forecasts. The company declared a $0.88 quarterly dividend, and analysts maintain a "Moderate Buy" rating with a consensus price target of $395.33.
2026-06-09 16:10:11
Artivion (AORT) reported a 17.5% year-over-year revenue increase to $116.3 million in Q1 2026, matching analyst expectations, amidst a mixed performance for the medical device and supply sector. Despite the revenue match, the quarter was characterized by a shortfall in analyst EPS estimates and slightly missed full-year revenue guidance. The company's growth was driven by strong performances in stent grafts, On-X, preservation services, and BioGlue.
